Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Project Grant

McMaster University

$279,225.00

Benchmarking a point-of-care test kit for detection of direct-oral anticoagulants

FY 2021-22

Summary
Blood clots cause many diseases. Thus blood thinners are commonly used medications, especially in those over 75 years old. Until 8 years ago the most common blood thinner was warfarin. Warfarin needs frequent blood tests to measure its effect because it interacts with foods and medications. New direct acting blood thinners are now prescribed more than warfarin. They are preferred because they have less interactions with foods and drugs. Blood is rarely tested for the new direct acting blood thinners, and, the tests to do so, need specialized laboratories with a turnaround of at least hours. Routine blood testing is not needed for these new blood thinners. But there are exceptions. Did the patient stop their blood thinner before surgery requiring spinal anaesthesia? If they did not, then they are at risk for paralysis. In a patient who presents with a stroke, did the patient forget to take their blood thinner? Knowing there was no blood thinner would mean that patient could be given function preserving clot busting drugs. A quick test that informs physicians that the patient has blood thinner in their blood or not would be a huge advance. We have developed a point-of-care finger-prick blood clotting test kit. It measures the activity of the key factor that makes clots, a result is obtained in under 40 minutes. This activity, and thus our test, is suppressed by the new blood thinners. In a broad population, we need to determine the activity, below which we can be sure that there is blood thinner in the blood. In patients who have stopped a direct acting blood thinner before surgery, we will do the specialized laboratory test and our test. This data will benchmark our test. Globally, each year over 500,000 people on new blood thinners need to stop them for surgery. Completion of this project would move our test kit closer to approval to be in the market. This would improve outcomes for these patients and generate economic benefit for Canada.
Program
Project Grant
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
461790
Name
Gross Peter L
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Circulatory and Respiratory Health
Theme2
Biomedical
Prcname2
Commercialization
Projecttitle
Benchmarking a point-of-care test kit for detection of direct-oral anticoagulants
Programtype2
Operating Grants
Orgnameinp2
McMaster University
Cihramount2
$279,225
Cihrequipment2
$0
Programname2
Project Grant
Keyworddelim
Atrial Fibrillation; Direct Acting Oral Anticoagulants; Point-Of-Care Test; Stroke; Thrombin Generation; Venous Thrombosis
Abstract
Blood clots cause many diseases. Thus blood thinners are commonly used medications, especially in those over 75 years old. Until 8 years ago the most common blood thinner was warfarin. Warfarin needs frequent blood tests to measure its effect because it interacts with foods and medications. New direct acting blood thinners are now prescribed more than warfarin. They are preferred because they have less interactions with foods and drugs. Blood is rarely tested for the new direct acting blood thinners, and, the tests to do so, need specialized laboratories with a turnaround of at least hours. Routine blood testing is not needed for these new blood thinners. But there are exceptions. Did the patient stop their blood thinner before surgery requiring spinal anaesthesia? If they did not, then they are at risk for paralysis. In a patient who presents with a stroke, did the patient forget to take their blood thinner? Knowing there was no blood thinner would mean that patient could be given function preserving clot busting drugs. A quick test that informs physicians that the patient has blood thinner in their blood or not would be a huge advance. We have developed a point-of-care finger-prick blood clotting test kit. It measures the activity of the key factor that makes clots, a result is obtained in under 40 minutes. This activity, and thus our test, is suppressed by the new blood thinners. In a broad population, we need to determine the activity, below which we can be sure that there is blood thinner in the blood. In patients who have stopped a direct acting blood thinner before surgery, we will do the specialized laboratory test and our test. This data will benchmark our test. Globally, each year over 500,000 people on new blood thinners need to stop them for surgery. Completion of this project would move our test kit closer to approval to be in the market. This would improve outcomes for these patients and generate economic benefit for Canada.
Competitiondate
202203
Approvedterm2
2 yrs 0 mth
Pinamesdelim
Gross, Peter L
Approvedterm
2 ans 0 mois
Cihrcontribution2
~ $279,225~ $0~